PIONEER-IBS: Pilot Trial Investigates Personalized Psychotherapy Approaches for IBS
A recent randomized controlled trial investigated various therapeutic methods based on individual patients’ symptom dynamics to analyze the feasibility of a personalized psychotherapy approach for patients...
A recent randomized controlled trial investigated various therapeutic methods based on individual patients’ symptom dynamics to analyze the feasibility of a personalized psychotherapy approach for patients with irritable bowel syndrome (IBS). A team of researchers from Germany conducted the study and published their findings in the Journal of Psychosomatic Research .
The investigators explained that it was important to evaluate psychotherapeutic treatment approaches for patients with IBS because the condition is “characterized by recurring gastrointestinal symptoms and substantial psychosocial burden.” Despite the burden of the disorder and the various therapeutic options available to patients, a superior treatment approach has not been identified, the study authors wrote.
A total of 79 patients participated in the study and completed symptom diaries once daily for 7 weeks to determine randomization. The investigators explained that they used the individual symptom patterns identified in participants’ diaries to assign patients, in a personalized or reverse-personalized manner, to eye movement and desensitization and reprocessing (EMDR) or gut-directed hypnotherapy (GDH) groups.
Continue reading
Watch a short ad to unlock the full article
The rest stays locked if you skip or close the ad early.
In addition, patients selected for the control group received “optimized treatment as usual (TAU).” Investigators highlighted primary and secondary outcomes of the study, which were study protocol feasibility and “changes in gastrointestinal and psychosocial measures after the interventions (T2) and at a three-month follow-up (T3),” respectively.
A total of 58 patients (73.4%) completed their assigned therapy and attended at least five sessions out of seven total sessions. Using the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS), the investigators observed high baseline symptom burden among participants (IBS-SSS: 314.19, STD ± 81.21).
Furthermore, the findings demonstrated a lack of “significant differences in secondary outcomes” across both “personalized and reverse-personalized therapy at T2 and T3.” Investigators highlighted that pre-post change scores among both intervention groups at T2 showed improved somatic symptom burden (SSS-8: P =0.003 personalized therapy; P =0.05 reverse-personalized therapy).
In reflecting on the results, the investigators underscored that PIONEER-IBS investigated “novel concepts of personalizing therapy.” “However, the benefit of treatment allocation based on individual symptom dynamics, the validity of personalization approaches and the efficacy of EMDR in specific IBS subgroups represent distinct but intertwined questions that require further evaluation,” they concluded.
References Rämisch M, et al. Journal of Psychosomatic Research. 2026 Oct 1;211:113003. doi: 10.1016/j.jpsychores.2026.113003
Article text via FreeNewsAPI. Rights remain with DocWireNews.
Read on publisher site → Opens DocWireNews in a new tab
